These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38041093)

  • 1. The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.
    Wei W; Shi F; Xu Y; Jiao Y; Zhang Y; Ou Q; Wu X; Yang L; Lai J
    J Transl Med; 2023 Dec; 21(1):874. PubMed ID: 38041093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.
    Beumer JH; Fu KY; Anyang BN; Siegfried JM; Bakkenist CJ
    BMC Cancer; 2015 Oct; 15():649. PubMed ID: 26438152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
    Vokes NI; Galan Cobo A; Fernandez-Chas M; Molkentine D; Treviño S; Druker V; Qian Y; Patel S; Schmidt S; Hong L; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Negrao MV; Gibbons DL; Vaporciyan A; Le X; Wu J; Zhang J; Rigney U; Iyer S; Dean E; Heymach JV
    Clin Cancer Res; 2023 Dec; 29(23):4958-4972. PubMed ID: 37733794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.
    Ricciuti B; Elkrief A; Alessi J; Wang X; Li Y; Gupta H; Muldoon DM; Bertram AA; Pecci F; Lamberti G; Di Federico A; Barrichello A; Vaz VR; Gandhi M; Lee E; Shapiro GI; Park H; Nishino M; Lindsay J; Felt KD; Sharma B; Cherniack AD; Rodig S; Gomez DR; Shaverdian N; Rakaee M; Bandlamudi C; Ladanyi M; Janne PA; Schoenfeld AJ; Sholl LM; Awad MM; Cheng ML
    Clin Cancer Res; 2023 Jul; 29(13):2540-2550. PubMed ID: 37097610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.
    Hwang J; Shi X; Elliott A; Arnoff TE; McGrath J; Xiu J; Walker P; Bergom HE; Day A; Ahmed S; Tape S; Makovec A; Ali A; Shaker RM; Toye E; Passow R; Lozada JR; Wang J; Lou E; Mouw KW; Carneiro BA; Heath EI; McKay RR; Korn WM; Nabhan C; Ryan CJ; Antonarakis ES
    Clin Cancer Res; 2023 Jul; 29(14):2702-2713. PubMed ID: 37126020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
    Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
    Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.
    Weber AM; Drobnitzky N; Devery AM; Bokobza SM; Adams RA; Maughan TS; Ryan AJ
    Oncotarget; 2016 Sep; 7(38):60807-60822. PubMed ID: 27602502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.
    Kennedy RD; Chen CC; Stuckert P; Archila EM; De la Vega MA; Moreau LA; Shimamura A; D'Andrea AD
    J Clin Invest; 2007 May; 117(5):1440-9. PubMed ID: 17431503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulated ATM gene expression and activated DNA crosslink-induced damage response checkpoint in Fanconi anemia: implications for carcinogenesis.
    Yamamoto K; Nihrane A; Aglipay J; Sironi J; Arkin S; Lipton JM; Ouchi T; Liu JM
    Mol Med; 2008; 14(3-4):167-74. PubMed ID: 18224251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the Fanconi Anemia DNA Repair Pathway by Phosphorylation and Monoubiquitination.
    Ishiai M
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologous recombination deficiency gene panel analysis results in synchronous endometrial and ovarian cancers.
    Kazanci F; Çelik ZY; Polat M; Karademir F; Erdem O; Şahin Fİ; Onan MA
    Rev Assoc Med Bras (1992); 2024; 70(10):e20240534. PubMed ID: 39356959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation at intronic repeats of the ataxia-telangiectasia mutated (ATM) gene and ATM protein loss in primary gastric cancer with microsatellite instability.
    Kim HS; Choi SI; Min HL; Kim MA; Kim WH
    PLoS One; 2013; 8(12):e82769. PubMed ID: 24324828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function.
    Collins NB; Wilson JB; Bush T; Thomashevski A; Roberts KJ; Jones NJ; Kupfer GM
    Blood; 2009 Mar; 113(10):2181-90. PubMed ID: 19109555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Fanconi anemia ID2 complex: dueling saxes at the crossroads.
    Boisvert RA; Howlett NG
    Cell Cycle; 2014; 13(19):2999-3015. PubMed ID: 25486561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Mou J; Hu T; Wang Z; Chen W; Wang Y; Zhang W
    Aging (Albany NY); 2020 Apr; 12(8):7465-7479. PubMed ID: 32329754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
    Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
    Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.